Viridian Therapeutics Shares Surge 35.6% After REVEAL-2 Phase III TED Success
VRDN•Viridian Therapeutics announced Phase III REVEAL-2 trial in 204 TED patients met primary endpoints with proptosis responder rates of 50% and 54% in four-weekly and eight-weekly cohorts versus 15% for placebo. The stock jumped 35.6% to open at $19.07 following data release that coincided with the Q1 earnings report.
1. Trial Design and Endpoints
The REVEAL-2 trial randomized 204 patients equally to receive elegrobart four-weekly, eight-weekly or placebo to evaluate proptosis responder rate per FDA guidance and overall responder rate per EMA guidance as its co-primary endpoints.
2. Efficacy Results
Proptosis responder rates reached 50% in the four-weekly cohort and 54% in the eight-weekly cohort versus 15% for placebo; overall responder rates were 47% and 54% respectively compared with 15% in placebo, with key secondary endpoints also met.
3. Market Reaction and Outlook
Shares opened 35.6% higher at $19.07 on May 5, driven by the positive Phase III data release coinciding with Q1 earnings, strengthening the case for elegrobart’s potential regulatory filings and commercial launch.
